TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nephros ( (NEPH) ) has provided an announcement.
On November 21, 2025, Nephros, Inc. entered into a new license and supply agreement with Medica S.p.A. to market and sell filtration products based on Medica’s ultrafiltration technology, replacing a prior agreement from December 2023. This agreement, effective through December 31, 2030, involves exclusive licensing rights, minimum annual purchase commitments, and mutual termination clauses, potentially impacting Nephros’s market positioning and operational strategy.
The most recent analyst rating on (NEPH) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Nephros stock, see the NEPH Stock Forecast page.
Spark’s Take on NEPH Stock
According to Spark, TipRanks’ AI Analyst, NEPH is a Neutral.
Nephros shows strong earnings performance with significant revenue growth and sustained profitability, which are the most impactful factors driving the score. Technical indicators support a positive trend, although the high P/E ratio suggests overvaluation. The company’s strategic innovations and expanding customer base further enhance its outlook.
To see Spark’s full report on NEPH stock, click here.
More about Nephros
Nephros, Inc. operates in the medical products industry, focusing on filtration products. The company collaborates with Medica S.p.A., an Italian manufacturer, to enhance its product offerings using Medica’s proprietary ultrafiltration technology.
Average Trading Volume: 70,481
Technical Sentiment Signal: Buy
Current Market Cap: $60.47M
For an in-depth examination of NEPH stock, go to TipRanks’ Overview page.